By Danielle Walsh, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic
The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic at MD Anderson is the first of its kind to focus on patients with inflammatory breast cancer (IBC). Since opening in October 2007, we've seen more than 300 IBC patients from across the country.
Treating IBC requires the coordinated efforts of every member of the oncology team. Our multidisciplinary team of experts in medical oncology, surgical oncology, radiation oncology, diagnostic radiology, pathology and IBC biology are passionate and committed to fighting IBC.
The team of breast medical oncologists dedicated to IBC includes Naoto Ueno, M.D., Ph.D., Vicente Valero, M.D., and Ricardo Alvarez, M.D. They are further supported by advanced practice nurse Pam Alizadeh, who is available to see patients every day.
Rounding out our team are radiologists Thomas Buchholz, M.D., and Wendy Woodward, M.D., diagnostic radiologist Wei Yang, M.D., and surgeons Anthony Lucci, M.D., and Gildy Babiera, M.D.
Breast Medical Oncology, considers it "a great honor and pleasure to direct the IBC clinical research with this highly motivated multidisciplinary team of professionals. As virulent as this disease is, the inflammatory breast cancer team responds with as much vigor and dedication to understand the biology of the disease and to develop novel therapies with the goal of eradicating IBC."
Unique to the Morgan Welch IBC Clinic is our IBC-specific and IBC-inclusive clinical trial portfolio available to patients. We lead the international IBC registry that collects epidemiological, pathological and historical information, as well as blood and tissue samples for future studies. We also offer a number of clinical trials investigating novel therapeutics in IBC.
- A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (HER2/neu) (Ricardo Alvarez, M.D., Principal Investigator)
- Phase II Study of Panitumumab, Nab-paclitaxel and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression (Naoto Ueno, M.D., Ph.D., Principal Investigator)
- A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced IBC or Non-IBC (Wendy Woodward, M.D., Principal Investigator)
- Phase II Study of Purging of CTCs From Metastatic Breast Cancer Patients (Naoto Ueno, M.D., Ph.D., Principal Investigator)
- A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients with Stage IV HER2-negative IBC and Local or Distant Relapse (Ricardo Alvarez, M.D., Principal Investigator)
- A Phase I/II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumor Overexpresses HER2 (Naoto Ueno, M.D., Ph.D., Principal Investigator)
- A Phase I/II Study of Entinostat and Lapatinib in Patients With HER2-positive Metastatic Breast Cancer in Women Where Trastuzumab Has Failed
- A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2 Positive Breast C
- A Phase II Study of Combination Chemotherapy of Ixabepilone, Capecitabine, and Bevacizumab for Patients With Inflammatory and Locally Advanced Breast Cancer, HER-2 Negative, Who Remain Non-Surgical Candidates After Neoadjuvant Treatment With Taxane and Anthracycline-Based Chemotherapy